Trial Profile
Study of safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2018
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Therapeutic Use
- 17 Jun 2018 Results (n=62) assessing safety and efficacy presented at the 23rd Congress of the European Haematology Association.
- 17 May 2018 New trial record
- 04 May 2018 Results published in the Bone Marrow Transplantation